391 related articles for article (PubMed ID: 31139863)
1. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
[TBL] [Abstract][Full Text] [Related]
2. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
3. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
4. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
[TBL] [Abstract][Full Text] [Related]
5. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
Pyun DH; Kim TJ; Park SY; Lee HJ; Abd El-Aty AM; Jeong JH; Jung TW
Mol Cell Endocrinol; 2021 Dec; 538():111464. PubMed ID: 34601002
[TBL] [Abstract][Full Text] [Related]
6. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis.
Singuru G; Pulipaka S; Shaikh A; Balaji Andugulapati S; Thennati R; Kotamraju S
Int Immunopharmacol; 2023 Nov; 124(Pt B):111070. PubMed ID: 37862737
[TBL] [Abstract][Full Text] [Related]
8. MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1.
Wang Y; Zhu K; Yu W; Wang H; Liu L; Wu Q; Li S; Guo J
Biochem Biophys Res Commun; 2017 Nov; 493(1):227-232. PubMed ID: 28899784
[TBL] [Abstract][Full Text] [Related]
9. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells.
Wen F; An C; Wu X; Yang Y; Xu J; Liu Y; Wang C; Nie L; Fang H; Yang Z
Int J Biochem Cell Biol; 2018 Jan; 94():133-145. PubMed ID: 29197627
[TBL] [Abstract][Full Text] [Related]
11. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
12. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes.
Yousefi Z; Nourbakhsh M; Abdolvahabi Z; Ghorbanhosseini SS; Hesari Z; Yarahmadi S; Ezzati-Mobasser S; Seiri P; Borji M; Meshkani R; Malek M
J Cell Physiol; 2020 Feb; 235(2):880-890. PubMed ID: 31256424
[TBL] [Abstract][Full Text] [Related]
13. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
14. Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy.
Stacchiotti A; Grossi I; García-Gómez R; Patel GA; Salvi A; Lavazza A; De Petro G; Monsalve M; Rezzani R
Cells; 2019 Sep; 8(9):. PubMed ID: 31500354
[TBL] [Abstract][Full Text] [Related]
15. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
Kong M; Peng Y; Qiu L
Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells.
Chang E; Kim Y
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31744213
[TBL] [Abstract][Full Text] [Related]
17. miR-29a Modulates GSK3β/SIRT1-Linked Mitochondrial Proteostatic Stress to Ameliorate Mouse Non-Alcoholic Steatohepatitis.
Yang YL; Wang PW; Wang FS; Lin HY; Huang YH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961796
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
19. C1q/tumor necrosis factor-related protein-6 attenuates TNF-α-induced apoptosis in salivary acinar cells via AMPK/SIRT1-modulated miR-34a-5p expression.
Qu LH; Hong X; Zhang Y; Cong X; Xiang RL; Mei M; Su JZ; Wu LL; Yu GY
J Cell Physiol; 2021 Aug; 236(8):5785-5800. PubMed ID: 33400820
[TBL] [Abstract][Full Text] [Related]
20. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
